Skip to main content
. 2013 Feb 1;36(2):189–196. doi: 10.5665/sleep.2370

Figure 1.

Figure 1

Patient disposition. aThe safety population includes all randomized patients who took at least one dose of study medication during the double-blind treatment phase of the study. bThe efficacy population includes all randomized subjects who took at least 1 dose of study medication and provided at least 1 LSOMOTN value. LSOMOTN latency to sleep onset following middle-of-the-night awakening.